// App-Quantinova.ai

1406 : Long‐term effectiveness of berotralstat (BCX7353) for the prophylaxis of hereditary angioedema (HAE) attacks: Results from the APeX‐S study

Researchers

Presenter

  • Reshef A

Principal Investigators

  • Maurer M

  • Kiani S

  • Wu AY

  • Stobiecki M

  • Kinaciyan T

  • Peter J

  • Aygoren-Pursun E

  • Cornpropst M

  • Nagy E

  • Murray S

  • Collis P

  • Farkas H

Medical Centers

  • Barzilai University Hospital, Ashkelon, Israel

  • Charite Univsmedizin Berlin, Berlin, Germany

  • The Royal Marsden Hospital, London, United Kingdom

  • Center for Allergy and Asthma Care, Central, Hong Kong SAR

  • Jagiellonian University, Krakow, Poland

  • Medical University of Vienna, Vienna, Austria

  • University of Cape Town Lung Institute, Cape Town, South Africa

  • University Hospital Frankfurt, Frankfurt, Germany

  • Dova Pharmaceuticals, Durham, United States

  • Semmelweis University, Budapest, Hungary

Locations

  • Israel

  • Germany

  • United Kingdom

  • Poland

  • Austria

  • South Africa

  • United States

  • Hungary

Companies

  • N/A

Study Components

Therapeutic Area

  • Genetic Disorder

Disease

  • Hereditary angioedema

Biomarkers

  • N/A

Drug/Treatment

  • BCX7353

Outcome

  • N/A

Study Design

  • N/A

Phase

  • III

Study Id's

  • NCT03485911

  • NCT03472040

Sponsors

  • N/A

Result

  • N/A

Copyright © 2026. QuantiNova All rights reserved